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This article overviews the important ethical and legal challenges of different steps of the
personalized medicine journey such as research, prevention, diagnosis and treatment by
discussing paradigmatic examples including biobanks, genetic tests and gene therapy. Sci-
entiﬁc progress in the area of genetics, the completion of the Human Genome Project and the
ability to sequence genomes for competitive prices have offered the promise of revolution-
izing healthcare and raised important challenges to classical paradigms in the biomedical
law and ethics ﬁelds. Issues such as informed consent, privacy and conﬁdentiality, and
discrimination require particular analysis in this context. In the last years the concept of
personalized medicine has been a source of considerable hype and hope. Law and ethics
should be important allies to limit the former and potentiate the later.
©  2014 Escola Nacional de Saúde Pública. Published by Elsevier España, S.L.U. All rights
reserved.
Desaﬁos  éticos  e  legais  da  medicina  personalizada:  exemplos
paradigmáticos  de  investigac¸ão,  prevenc¸ão,  diagnóstico  e tratamento
Palavras-chave:
Medicina personalizada
Biobancos
Genética
r  e  s  u  m  o
Este artigo sumariza alguns dos desaﬁos ético-legais mais importantes das diferentes
etapas da medicina personalizada, partindo da investigac¸ão, passando pela prevenc¸ão e
pelo  diagnóstico, e terminando no tratamento. Esta análise é realizada através da dis-
cussão de exemplos paradigmáticos de cada etapa, como os biobancos, os testes genéticosO progresso cientíﬁco na área da genómica, a ﬁnalizac¸ão do Pro-Genómica e  a terapia génica. 
Testes genéticos
Terapia génica
Direito e ética em saúde pública
jeto  do Genoma Humano e a capacidade de sequenciar genomas inteiros a prec¸os cada
vez  mais competitivos originaram a promessa de revolucionar a área da saúde e colo-
caram desaﬁos importantes a alguns conceitos tradicionais nas áreas da ética e do direito
biomédico. Consequentemente, temas como o consentimento informado, a privacidade e
 Sections 2 and 3 of this article are based on and continue the work started in Faria, PL and Cordeiro, JV “Public Heath: ethical and legal
challenges in a nutshell”. In: Yann Joly & Bartha Maria Knoppers, eds., Routledge Handbook of Medical Law and Ethics, Routledge, 2014.
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a conﬁdencialidade e a discriminac¸ão exigem uma análise atenta e particular neste con-
texto. Nos últimos anos, o conceito de medicina personalizada tem sido, simultaneamente,
uma fonte de expetativas exageradas e de grande esperanc¸a. O direito e a ética devem ser
aliados fundamentais para limitar as primeiras e potenciar a última.
©  2014 Escola Nacional de Saúde Pública. Publicado por Elsevier España, S.L.U. Todos os
direitos reservados.
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information, can vary signiﬁcantly in terms of nature, size,
13ntroduction
ersonalized medicine is a term that refers to medicine that
s speciﬁcally designed to a given individual based on its
enomic information.1 In the last years, particularly since
equencing genomes left the realm of science ﬁction and
ecame a fact of life, the concept of individualized healthcare
as become a source of great hope. In parallel, the capacity to
se genetic data to develop speciﬁc tailor-made therapies in
he immediate future has been greatly exaggerated by some,
enerating unfounded hype. In order to separate hype from
ope in this context we must strive to fully understand and
ot underestimate both the potential and the limitations of
urrent knowledge about the genetic basis of disease. With
hat in mind, there is little doubt that the advances in genetics
nd genomics in recent decades have been outstanding. Of
hese, the Human Genome Project (HGP), due to its massive
imension and the unprecedented attention it received
rom outside the scientiﬁc community has polarized most
iscussions.2,3 However, irrespective of how enthusiastic or
keptical we  are about the progress that the HGP has already
orged, we  must not isolate this project from other work –
ast, present and future.4
A global analysis of the advances in the area of genetics and
enomics highlights one trend that is common to most sci-
ntiﬁc and technological progress – exponential progression.
his trend can be illustrated by a popular anecdote about the
rigin of the board game of chess. The story goes that some-
ime during the 6th century a vizier made an extraordinary
ffer to an Indian ruler: a beautiful chessboard. The king was
o impressed by it that he gave the vizier the possibility to
hoose any present of his liking. Used to be met  with extrav-
gant requests, the king was surprised when the vizier asked
or a grain of wheat for the ﬁrst square of the chessboard, two
rains for the second, four for the third, and so on, doubling
he amount of wheat for each new square. Unaware of the con-
equences, the king ordered his men  to calculate the amount
f wheat necessary to satisfy the vizier’s request and give it to
im as promised. As the calculation was completed, the king
ealized it was not possible to ﬁnd enough wheat in the entire
orld to satisfy the request.5
Like the king in this story, most of us do not easily grasp the
ull implications of the exponential function at ﬁrst. It is more
ntuitive to think in linear terms. Therefore, as advances in sci-
nce are sometimes wrongly placed in a linear scale instead
f in an exponential one, future context is not properly eval-
ated and estimations of future ramiﬁcations miss the point.
lmost eight millennia went by between the agricultural and
he industrial revolutions. Yet, only one hundred and twentyyears passed between the industrial revolution and the cre-
ation of the light bulb.6 Human communication in today’s
world is largely web-based but the internet was only launched
worldwide less than 25 years ago.7
The same principle applies to progress in the area of genet-
ics and genomics. Following on centuries of questioning that
led to Mendel’s laws of genetics in the second half of the nine-
teenth century, vital breakthroughs emerged in the last ﬁfty
to sixty years. These include the discovery of the structure
of DNA, which was reported in 1953 and the genetic code in
1966, which led to the establishment of the so-called “cen-
tral dogma” of molecular biology (DNA makes RNA makes
Protein).4,8,9 A decade or so later, Sanger and others developed
DNA sequencing methods.10 In 1991 the HGP was launched
and in 2003 it was ﬁnished.2,11 In the last decade, the genomes
of different species have been sequenced – including the ﬁrst
human personal genome in 2008 – and the ﬁrst synthetic
genome was produced and used to start up a bacterial cell.4,12
Also, different projects have sprouted from these advances,
such as the sequencing of disease genomes, including can-
cer, the development of biobanks or the offering of genetic
tests directly to consumers.4 Hence, in science in general and
in genetics and genomics in particular, progress is happening
fast and its ramiﬁcations are multiple and difﬁcult to estimate
and predict.
This article aims to analyze and discuss relevant challenges
posed to law and ethics by some of the advances in genet-
ics and genomics and the possibility of achieving meaningful
personalized medicine in the future. Much  has been writ-
ten about the advent of genomics and, particularly, about its
ethical and legal implications.3 The conclusions intertwine
with developments in other scientiﬁc areas and with broader
socioeconomic transformations, which involve complex
issues such as privacy, liberty, discrimination and market eco-
nomics. Therefore, this article can only aim to offer a general
analysis on this topic. It aims to discuss different steps of the
personalized medicine journey through a law and ethics lens,
including research, prevention and diagnosis, and, ﬁnally,
treatment. The examples that will be discussed for each step
are biobanks, genetic tests and gene therapy, respectively.
Research:  biobanks
Biobanks, which in general terms can be described as orga-
nized collections of biological material and/or associatedaim, duration, ownership or governance model. This vari-
ation contributes to the difﬁculty in selecting clear and
precise legal deﬁnitions, which are important for establishing
b l i c a
and the human right to enjoy the beneﬁts of science and its
applications.33,e166  r e v p o r t s a ú d e p ú 
adequate regulatory regimens. In the last years, biomedical
research biobanks have gained impressive momentum, par-
ticularly because: (i) they facilitate the testing of basic science
observations in samples with clinical relevance; (ii) expand
access to a large number of samples confering greater signif-
icance to research studies; (iii) guarantee uniformization of
sample preparation and improve reproducibility of research
results; (iv) potentiate research collaborations between scien-
tists, clinicians, ethicists and other professionals.14,15
In terms of ethical and legal challenges, the debate
has intensiﬁed since the historic case of the national DNA
database in Iceland, which received legal support by the 1998
Act on Health Sector Database (HSD) of the national Parlia-
ment. Such Act allowed the constitution of a nation-wide
biobanka and its licensing to a private company, deCODE
Genetics. These facts raised signiﬁcant concerns, namely
related to privacy of individuals included in the databank,
the selected informed consent processes and the possible col-
lision between public interest and proﬁt-oriented company
interests.16,17,b Since the Icelandic HSD case great discus-
sion surrounding the ethical, legal and social issues and
implications of research biobanks has ensued. In summary,
these issues are varied and can usefully be divided in main
clusters as Solbakk and others have suggested18: (i) issues
concerning how biological materials are entered into the
bank; (ii) issues concerning research biobanks as institutions;
(iii) issues concerning under what conditions researchers can
access materials in the bank; problems concerning ownership
of biological materials and of intellectual property arising from
such materials; (iv) issues related to the information collected
and stored, e.g. access-rights, disclosure, conﬁdentiality, data
security, and data protection.
As these authors point out there is considerable overlap
between clusters and certainly all are very relevant. This arti-
cle will focus on the challenges to informed consent and to
privacy and conﬁdentiality.
Informed consent is the cornerstone of biomedical ethics19
and, in most countries, participation in a biobank for research
purposes requires informed consent procedures, as does
participation in most research projects that require the use of
biological material.20,21 This requirement constitutes one
of the most fundamental norms of research regulation,
which is condensed in the ﬁrst sentence of the Nuremberg
Code: “The voluntary consent of the human subject is absolutely
essential”.22 Accordingly, the main international law and
ethics normative instruments related to research on genetic
data either directly or indirectly refer to the primacy of the
human being and consequently to the primordial importance
of informed consent.23,c Such principles are also inscribed
a It was in fact a tripartite biobank – one biobank containing DNA
samples from a signiﬁcant proportion of the Icelandic population,
and  two separate databases consisting of genealogical information
and health records.
b More recently, some of these issues have re-emerged, following
two signiﬁcant ﬁnancial moves involving the company, one in 2009
(deCODE sold the database to avoid bankruptcy) and a more recent
one in 2012 (deCODE was bought by another company).
c See as examples the Convention on Human Rights and Biomedicine
(Council of Europe 1997, article 2); the Declaration of Helsinki (WMA . 2 0 1 4;3 2(2):164–180
in the national legal frameworks of different countries,24,d
both at a Constitutional and infra-Constitutional level.
Hence, most regulations require that biological material and
associated information are only used for research purposes
with the knowledge and consent of the person from which
these were derived. These rules apply also to large-scale
research projects such as biobanks. On the contrary, there is
considerable debate about whether the traditional informed
consent paradigm is appropriate for these projects. Even
assuming the terminology “informed consent” is appro-
priate, which is not straightforward, the adequate type of
that informed consent is debatable.25,26 Different authors
present different arguments to sustain that the classical
models of informed consent are not adequate to genetic
biobanks and should be adapted or substituted by different
paradigms.21,27–31 These arguments are varied and include:
(i) the scope of the original consent regarding secondary uses
of samples and the impracticality of the constant need for
re-consent; (ii) the complex issue of authorization or request
for sample destruction; (iii) the nature of the information to
provide to donors; (iv) the difﬁculties in fully guaranteeing
genetic sample anonymity; and (v) the lack of clear and
uniform rules to delimit the extent of property rights over
samples and research results.32–34 Moreover, as biobanks are
often inserted in large national and international networks,
informed consent models (or alternative agreements) must
either be universal or easily adaptable to permit information
and sample sharing while still accommodating ethical, legal,
social and cultural differences.35–38 Taken all this together
and factoring in public perceptions, other authors propose
that informed consent models – of any type – should be
averted. Alternatively, it should be assumed that participants
are willing to delegate decisions on proxies, which most of the
times are research ethics committees, that are better placed
to evaluate and manage the situation.39,40 On the other hand,
others suggest adopting undetermined models such as broad
or open consent,25,28,41 or alternatives such as conditional
authorizations for sample donation and gift agreements.25,30
In conclusion, clear rules are both lacking and essential
in this ﬁeld. Efforts to select the most adequate agreements
for biobank participation must be mindful that individual
and fundamental values such as liberty and autonomy must
be balanced and made compatible with the common good2013, articles 24–29); the Universal Declaration on the Human Genome
and Human Rights (UNESCO 1997, article 5(b), article 5(e)); and the
International Declaration on Human Genetic Data (UNESCO 2003, arti-
cle  2(iii), article 6(d), article 8, article 9).
d Including Iceland. Icelands´ original Act on Health Sector
Database from 1998 did not specify the requirement for informed
consent but set up an opt-out scheme instead (article 8). Subse-
quently, the Iceland Supreme Court declared the Act on Health
Sector Database unconstitutional, which prompted the inclusion
of an informed consent requirement in the Act.
e See: Universal Declaration of Human Rights (United Nations 1948,
articles 27 and 29/2); International Covenant on Economic, Social and
Cultural Rights (United Nations, 1966, article 15).
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One additional yet related and fundamental issue that
eserves ethical and legal analysis in the context of biobanks
s that of privacy and conﬁdentiality.25,42–46,f This issue is
articularly important because genetic information has the
nherent potential to link biological material to the individual
rom which it originated and, moreover, because the infor-
ation included in biobanks for research purposes is usually
inked to other health data.47 Furthermore, respect for pri-
ate life, in the case of genetic information deserves careful
nalysis as this information relates not only to the individ-
al but also to his/her family.48,g In the case of privacy rights
nd genetic information included in biobanks, we can once
gain turn to Iceland’s Act on Health Sector Database for histori-
al context. In a very interesting case from the last decade, the
celand Supreme Court held that in the case of genetic infor-
ation, privacy rights are broadened beyond an individual
phere to encompass close family members (in this partic-
lar case a daughter).49,50 Hence, in the context of genetics,
ndividual rights can blend into family rights. Therefore, this
hould be explained in the clearest terms to biobank donors,
hich is a very difﬁcult task. Furthermore, conﬁdentiality
ights (and their possible limitations), which lie downstream
f privacy rights, should also be explained, understood and
espected. Weighting and balancing of the values at stake
re still important despite the fact that most patients choose
o share information of genetic risk with family members.51
herefore, it is essential to implement safeguards to pro-
ect conﬁdentiality agreements in the context of biobanks
nd to prevent or minimize conﬁdentiality breaches that
ould considerably damage public trust. Such trust is essen-
ial to potentiate these fundamental research infrastructures
hich offer great hope for future diagnosis and treatment of
isease.
revention  and  diagnosis:  genetic  tests
ince the beginning of the HGP, particularly from the second
alf of the last decade onwards, the costs of genetic sequenc-
ng have decreased dramatically.52,h In parallel, genetic testing
s now widely available and can assume multiple forms,
hich complicates the adoption of uniform deﬁnitions for
egulatory purposes.53,54 For example, genetic tests can be
erformed at different stages – preconception, preimplanta-
ion (on human embryos), prenatal (on a fetus), on newborns,
uring childhood and adulthood; use different techniques
 chromosome analysis, ﬂurescence in situ hybridization
FISH), DNA microarrays, whole exome sequencing (WES) or
hole genome sequencing (WGS), and serve different pur-
oses – diagnostic, predictive of disease or response to drugs,
f This subject is also central to debates in public health.
ee, for example, the Draft NIH Genomic Data Sharing Pol-
cy  Request for Public Comments of late 2013, available here:
ttp://www.gpo.gov/fdsys/pkg/FR-2013-09-20/pdf/2013-22941.pdf.
g See also: International Declaration on Human Genetic Data
UNESCO 2003, article 4 a(ii)).
h See also DNA Sequencing Costs, Data from the
HGRI Genome Sequencing Program (GSP) available here:
ttp://www.genome.gov/sequencingcosts/. 0 1 4;3 2(2):164–180 167
forensic or research. Furthermore, as testing human genes and
genomes can now constitute a proﬁtable marketable activity,
gene tests are currently offered not only by public laborato-
ries but also by private companies.55 The expansion of genetic
testing is such that under the promise of individualized solu-
tions, public laboratories and private companies now offer to
diagnose genetic disease or test our predisposition to develop
different conditions in the future, all this at competitive prices.
There are currently genetic tests that cover diseases such as
certain types of cancer, diabetes, cardiovascular and mental
diseases, conditions such as obesity, and attributes such as
muscle performance, and baldness, among others. More,  our
individual responses to particular drugs and chemicals,
our ancestry details and even genetic matchmaking are all
testable or promised as such so long as we  agree to provide
a sample of our DNA for analysis, which in most cases is as
simple and risk-free as providing a blood or saliva sample. In
this complex context, it is essentil to separate hype from hope.
Indisputably, this genetics-for-all reality (maybe not really for
all as discussed in the ﬁnal section) yields great potential but
is also accompanied by signiﬁcant challenges, some of which
are ethical and legal.56
Many of these challenges are posed by the expanding real-
ity of direct-to-consumer (DTC) genetic tests, which as the
name indicates are offered by companies and laboratories
directly to consumers via the internet, television or other
media, without the involvement of an healthcare provider
or practitioner. In some cases, these tests are offered using
intricate marketing and results communication practices
involving parties from different jurisdictions, which com-
plicates an ethical and legal analysis.56 Nonetheless, some
challenges can be clearly identiﬁed. Firstly, without the inter-
mediation of a healthcare practioner or the direct access to a
genetic counselor consumers are unprotected from the per-
nicious effects that may arise from misleading or unhelpful
information. In this context, it is important to pay attention to
the genetic test’s analytical validity, clinical validity and, clin-
ical utility.55,56 The analytical validity, a measure of a test’s
detection accuracy, must be well established and certiﬁed.
This necessity has prompted efforts on different countries to
license laboratories that perform genetic testing by requiring
speciﬁc professional training, clear record keeping standards
and periodical assessment of methodologies.56 Furthermore,
regulatory lacunae should be ﬁlled by careful adaptation
of quality control norms already in place for other clinical
laboratory tests or pregnancy tests, for example. Secondly,
translating a positive result into clinical signiﬁcance, which
determines the clinical validity of the test, is not straight-
forward and involves mastering accurate scientiﬁc notions of
probability, risk, and variance. These concepts are difﬁcult to
estimate, to explain and to be fully understood. Nonetheless,
the test’s results and limitations should be explained (and
understood) as clearly as possible. Thirdly, we  need to consider
the tests’ clinical utility, or the usefulness of the test’s results
in terms of prevention, diagnosis or treatment. Undoubtedly,
the utility of a positive or negative result is difﬁcult to esti-
mate, particularly when no therapy or prophylactic measures
are availlable. Hence, the decision to take a genetic test should
be preceeded by a comprehensive informed consent process
that includes discussion about what the test can and cannot
b l i c a
niﬁcant examples of how genetic data can improve treatment
options.72–75 Concurrently, when we think about personalized
medicine most of us think of administering the right drug for168  r e v p o r t s a ú d e p ú 
predict and the existence or inexistence of targeted thera-
peutical or preventive strategies.57 Misleading information
potentially resulting in delayed visits to the doctor, raised anx-
iety and stress or batteries of unnecessary additional tests,
must be avoided or mitigated. In parallel, the privacy of genetic
information should also be protected42 and it is essential to
guarantee that the tests’ results are conﬁdential and not acces-
sible to third parties without consent.
Overall, clear boundaries for DTC genetic testing should be
established, including conditional involvement of healthcare
providers and professional couseling; standards for premarket
reviews; limits to advertising and marketing; speciﬁc oversight
of results reports; delimitation of provisions from public budg-
ets and health insurance coverages.58 To enforce these rules,
public powers may need to intervene. In a recent example from
the USA, concern surrounding some of these issues, partic-
ularly the lack of analytical and clinical test validation, test
advertisement without premarket approval, and the use of
information from consumers, led the FDA to issue a warning
to the DTC genetic tests company 23andMe, asking it to stop
returning results to consumers until completion of a review
process.i In response, the company suspended its health-
related genetic tests to comply with the directive and latter
presented the appropriate corrective measures.59,j This pro-
cess, although perceived by some as an unjustiﬁed ingerence
in a matter of personal liberty and individual autonomy,60
demonstrates that public health authorities play a key role
in demanding the necessary safety and quality standards for
genetic tests in order to protect consumers.59
On a different note, as laboratories expand analysis and
look beyond single genes, the issue of incidental ﬁndings
gains importance. Should patients be informed about ﬁndings
in genome regions that differ from the focus of the original
search? And what if that search is conducted without seek-
ing the patient’s consent? These questions have generated a
fair amout of discussion in Europe and the USA recently61,62,k
and some of the answers, which are currently straightforward
for standard medical tests, might require additional ponder-
ing in the case of genetic tests.63–65 Nonetheless, according to
relevant legal norms, the informed consent paradigm and the
principle of patient autonomy, patients have a right to decide
what to be and not to be tested for. Furthermore, they also have
a right to know and a right not to know.62,66 Being mindfull of
these patient’s rights without neglecting speciﬁc challenges
posed by genetics is the best (and perhaps only) way to extract
the full potential of genetic tests for medicine.
Importantly, particular and added attention must be ded-
icated to prevent unrestricted testing of the most vulnerable.
Most international ethical and legal norms are clear in estab-
lishing that informed consent to procedures involving those
i FDA Warning Letter available here: http://www.fda.gov/iceci/
enforcementactions/warningletters/2013/ucm376296.htm.
j FDA Close Out Letter available here: http://www.fda.gov/ICECI/
EnforcementActions/WarningLetters/ucm391016.htm.
k See also the following update from the American College
of  Medical Genetics and Genomics: https://www.acmg.net/docs/
Release ACMGUpdatesRecommendations ﬁnal.pdf. . 2 0 1 4;3 2(2):164–180
who are incapable of consenting is fundamental.l Such con-
sent should be given by legal representatives only after being
provided with sufﬁcient information “regarding the purpose and
the nature of the test, as well as the implications of its results”.m
Furthermore, whenever possible, the will of the person being
tested should be considered in proportion to his/her degree of
maturity and capacity to understand,n which underlines the
importance (and difﬁculty) of transmiting and understanding
notions such as probability and risk.
In terms of testing the most vulnerable, the subject
of genetic testing in children67 and speciﬁcally of New-
born Genetic Screening Programs [NGSP] is particularly
important.68,69 Firstly, in terms of informed consent, the role
of parents and legal representatives is not always clear.70
One one hand, parental consent seems necessary, as par-
ents are in a privileged position to defend the children’s own
interest, most tested diseases are rare and a possible false
positive result will cause unnecessary stress. On the other
hand, the overall beneﬁts of testing far out-weigh individ-
ual harms and bureaucratic procedures place considerable
burdens on health systems. This dillema is ongoing and for
example for different NGSP, voluntary, opt-in, opt-out, con-
ditional, implied and mandatory consent models have been
proposed and selected.68,70 Ultimately, decisions on a regu-
latory level should respect human rights, consider practical
aspects and all availlable options, take into account the val-
ues of each society and be reviewed periodically in order to be
adjusted if necessary.
In conclusion, different genetic tests pose different reg-
ulatory challenges and require dedicated attention.71 The
difﬁculties in establishing general risk–beneﬁt analyses in this
context justiﬁes the need for functional, nuanced and adapt-
able legal and ethical responses that simultaneously protect
individual rights and permit the advancement of medicine
and science.
Treatment:  gene  therapy
Discovering the genetic basis of disease, making risk predic-
tions based on genetic information and improving diagnostics
are the ﬁrst steps toward a cure. Advances in research,
prevention and diagnostics should be accompanied by the
development of valid therapies. There are, particularly in the
ﬁeld of pharmacogenomics, important and already very sig-l See, for example, the Declaration of Helsinki (WMA 2013, articles
19–20 and 29); the Additional Protocol to the Convention on Human
Rights and Biomedicine, concerning Genetic Testing for Health Purposes
(Council of Europe 2008, articles 9–12); the Convention on Human
Rights and Biomedicine (Council of Europe 1997, articles 5–6); and
the  Universal Declaration on the Human Genome and Human Rights
(UNESCO 1997, article 5).
m Additional Protocol to the Convention on Human Rights and
Biomedicine, concerning Genetic Testing for Health Purposes (Council
of Europe 2008, article 11).
n Convention on Human Rights and Biomedicine (Council of Europe
1997, article 6).
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he right patient at the right time. In parallel to the advances
n pharmacogenomics, other genetics-based treatments have
een developed, including gene therapy. Different gene ther-
py deﬁnitions exist and two of them are particularly relevant
rom an ethical and legal perspective because they originate
rom the competent regulatory agencies in both the USA and
urope. According to the European Medicines Agency (EMA),
ene therapy medicinal products must have two characteris-
ics:
(a) “contain an active substance which contains or consists of a
recombinant nucleic acid used in or administered to human
beings with a view to regulating, repairing, replacing, adding
or deleting a genetic sequence;
b) its therapeutic, prophylactic or diagnostic effect relates directly
to the recombinant nucleic acid sequence it contains, or to the
product of genetic expression of this sequence”.76
As for the FDA, gene therapy products are deﬁned as “prod-
cts that mediate their effects by transcription and/or translation
f transferred genetic material and/or by integrating into the host
enome and that are administered as nucleic acids, viruses, or genet-
cally engineered microorganisms. The products may be used to
odify cells in vivo or transferred to cells ex vivo prior to admin-
stration to the recipient”.77
As the complexity of both deﬁnitions illustrates, gene ther-
py can be performed in very different ways and originate
ifferent types of genetic alterations. An essential ﬁrst dis-
inction in terms of gene therapy regulation is between germ
ine and somatic genetic changes. The former involves genetic
lterations that can then be passed on to the offspring and the
atter consists in genetic changes that are restricted to
he individual and not passed on to future generations.78
erm line gene therapy (or the broader term “inheritable
enetic modiﬁcation”79,80) is prohibited for safety and eth-
cal reasons in most countries and, directly or indirectly,
eserves the attention of international biolaw and bioethics
ocuments.81–84,o On the contrary, the limits of somatic gene
herapy have been the subject of intense debate in the last
ecades and are far more  controversial, particular for safety
easons.78,85,86 Ever since the ﬁrst FDA-approved gene therapy
rial in September 1990 in the USA, which aimed at treat-
ng the monogenetic disease adenosine deaminase deﬁciency
ADA-SCID), several other trials were approved in the USA
nd elsewhere, including Europe.78 Nonetheless, the issue of
atient safety became a serious concern following the death
f 18-year old Jesse Gelsinger during a gene therapy trial at
he University in Pennsylvania, in 1999.87,88 This tragic event
rompted the scientiﬁc and legal communities to pause and
eassess the methodologies applied to gene therapy in both
elds. Gelsinger’s death was directly related to the adenovirus
ector used to deliver the gene (in his case the ornithine tran-
carbamylase gene), which elicited a fatal immune reaction.
o See also: Convention on Human Rights and Biomedicine (Coun-
il of Europe 1997), Universal Declaration on Bioethics and Human
ights (UNESCO 2005), Universal Declaration on the Human Genome
nd Human Rights. (UNESCO 1997), Declaration of Helsinki (WMA
964). 0 1 4;3 2(2):164–180 169
In other circumstances, another vector type used in gene ther-
apy – retrovirus – has caused oncogene activation and cancer.
The most prominent cases were those of the French children
who developed leukemia as a result of their participation in
gene therapy trials for X-linked severe combined immunode-
ﬁciency (SCID-X1), during the ﬁrst half of the last decade.89–92
In terms of patient safety, the challenge lies on how to reason-
ably estimate risks and beneﬁts, be it for trial participants in
experimental therapies or for patients in the case of approved
therapies.86 Therefore, a rigorous informed consent process
is particularly important in order to guarantee that the risks
and potential beneﬁts are properly explained (and not exag-
gerated) and understood. Autonomous informed decisions are
only made when the subject is competent, aware of potential
risks, has access to a reasonable estimation of beneﬁts and
is free from coercion.19 Hence, like in other therapies, spe-
cial attention must be paid to the most vulnerable, such as
the terminally ill, in order to guarantee that the differences
between clinical care and clinical research are properly clari-
ﬁed and understood.93–95 Furthermore, informed decisions are
only possible once relevant conﬂicts of interest affecting inves-
tigators and/or clinicians are fully disclosed and appropriate
measures are in place to guarantee that those conﬂicts do not
damage the integrity of the process.86
Since Jesse Gelsinger, gene therapy has come a long way
in dealing with ethical issues, technical obstacles and safety
concerns. Concurrently, the number of approved and con-
ducted trials worldwide has grown signiﬁcantly in the last
years.96 Therefore, it is expected that an expanding number
of gene therapy products will be approved for clinical use in
the near future. The ﬁrst ever approval occurred a decade
ago in China, but again not without ethical controversy. In
2003 and 2005, the Chinese State Food and Drug Administra-
tion (SFDA), approved the products Gendicine and Oncorine
for clinical use (recombinant adenoviruses containing the
tumor suppressor-gene P53 for treatment of head-and-neck
squamous cell carcinoma and nasopharyngeal carcinoma,
respectively). Notably, this approval was given without prior
conduction of phase III clinical trials.97–99 Conduction of phase
III clinical trials for gene therapy is sometimes exceptionally
challenging, especially in the case of monogenic disorders,
which have low prevalence within a population making
patient recruitment particularly difﬁcult. However, that was
not the case in the swift approval of Gendicine and Oncorine
in China, which seem to have resulted more  from an overall
permissive regulatory framework than from the impossibility
to meet practical contingencies. Importantly, discrepant reg-
ulatory landscapes of innovative therapies in different parts
of the world can have signiﬁcant ramiﬁcations that deserve
ethical and legal attention such as the expanding reality of
medical tourism that has been extensively debated in the con-
text of stem cell-based therapies but to which gene therapy is
no exception.100–102
The reduced recruitment pool for large clinical trials and
the lack of interest from investors in developing therapies for a
small market have long been identiﬁed as obstacles in the case
of most orphan diseases and therefore apply also to different
gene therapies. These obstacles have been tackled by dedi-
cated legislation in some countries, including the USA, Japan,
b l i c a170  r e v p o r t s a ú d e p ú 
Australia and also in the European Union.p More  recently, as
gene therapy clinical trial sponsors became more  aware of reg-
ulatory constraints, increasing numbers of gene therapies are
being developed as orphan drugs in order to make the most
of the ﬂexibility that these legal regimes allow.103 Remark-
ably, in July 2012, gene therapy for an ultra-orphan disease,
lipoprotein lipase deﬁciency, was historically approved by the
EMA.104,q Hence, the ﬁrst – and so far only – gene therapy prod-
uct approved for clinical use outside China (alipogene tipar-
vovec, also known as Glybera, an adeno-associated viral vector
carrying the LPL gene) beneﬁted from regulation that took
into account the difﬁculty in obtaining data in rare diseases
and considered evidence derived from a very small number
of patients.105 In spite of this, the approval process of Glybera
was not straightforward and exposed the difﬁculties of prod-
uct evaluation and authorization that companies developing
gene therapy products face today.103,106 Some of these difﬁcul-
ties, prominently time and ﬁnancial pressures and the lack of
predictability and precise criteria for future approval can jeop-
ardize ongoing research and development efforts96 and there-
fore require dedicated attention from regulatory bodies.105
As gene therapy becomes clinically available an additional
issue that begs further ethical analysis is that of its acceptable
aims. In which medical contexts is it acceptable to consider
genetic alterations – in all conditions or only in severe ones?
And if we  choose the latter what should be considered as
“severe” and how often should such assessment be revised?
In fact, deciding on whether or not a given medical condition
is worthy of genetic intervention is a complex decision that
invites careful consideration. In order to do so, speciﬁc disease
mechanisms, individual circumstances of patients, potential
beneﬁts and expected harms must be taken into account. Fur-
thermore, gene therapy is expensive therapy. Therefore, the
questions of access, equality and, from a provider’s perspec-
tive, resource allocation, are critical issues to be dealt with also
by ethics and the law. The human right to enjoy the beneﬁts of
science and its applications should be balanced by appropriate
public and private funding schemes that combat the poten-
tial for deepening inequality and the onset of new sources of
discrimination.
Genetics  and  genomics:  diversity
and discriminationIn order to take full advantage of the potential of personalized
medicine we  must distinguish hype from hope. Sequencing
p See, amongst others: USA – Orphan Drug Act (1983), Japan –
Orphan Drug Regulation (1993), Australia – Orphan Drug Policy
(1998), EU – Regulation (CE) N◦141/2000 (2000). More info at:
http://www.orpha.net/consor/cgi-bin/Education AboutOrphan
Drugs.php?lng=PT&stapage=ST EDUCATION EDUCATION ABOUT
ORPHANDRUGS COMPARISON.
q More information here: http://www.ema.europa.eu/ema/index.
jsp?curl=pages/news and events/news/2012/07/news detail
001574.jsp&mid=WC0b01ac058004d5c1, here: http://www.ema.
europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/002145/human med 001480.jsp&mid=
WC0b01ac058001d124 and here: http://ec.europa.eu/health/
documents/community-register/html/o194.htm. . 2 0 1 4;3 2(2):164–180
our genomes has become increasingly cheaper and we  are
now able to access an amount of data that was unimaginable a
few years ago. However, our capacity to manage and interpret
such big data is still insufﬁcient to fully understand, prevent,
diagnose and treat disease. Furthermore, as we  trust scien-
tiﬁc progress to help us achieve a better health, we must also
confront ourselves with the downsides of the personalized
medicine endeavor, in order to properly address them.
One of the most important risks that should be mentioned
is that of genetic discrimination. In this respect, I select one
sentence from South Africa’s anti-apartheid activist and Nobel
Peace Prize laureate Archbishop Desmond Tutu that properly
illustrates the basis for this discussion. Writing for the journal
Science about the commemoration of the 10th anniversary of
the HGP, he said:
“My  dream is that by including all peoples in understanding
and reading the genetic code we  will realize that all of us
belong in one global family – that we are all brothers and
sisters. Wow!”107
In 2010, Tutu had donated his own cells for the study
of genetic diversity. Results from that study showed that he
shared ancestry with a Kalahari Bushman from Namibia.108
These and other ﬁndings deserved the following comments
from Webb Miller, a professor of biology at Penn State Univer-
sity and co-author of the study:
“On average there are more  genetic differences between
any two bushmen in our study than between a European
and an Asian”, and:
“To know how genes affect health, we need to see the full
range of human genetic variation, (. . .)”.r
Fundamentally, the beauty of genetic diversity should be
studied and understood in parallel with the universality of our
human heritage. Simultaneously, we should all be protected
from interpretations that may lead to genetic discrimina-
tion. Hence, biobanks that selectively target a subset of the
population based on social notions of race or the actions of
employers, insurers or governments that use genetic informa-
tion resulting from genetic tests to favor a given genetic trait,
are all forms of genetic discrimination that may constitute
a violation of human rights. Furthermore, genetic interven-
tions in the context of gene therapy could also involve a risk
of discrimination that should not be underestimated. Firstly,
strictly speaking of somatic interventions, these therapies are
extremely expensive and are expected to remain so in the near
future. This fact should highlight the importance of fairness
and equality in access to health – which are elements of the
human right to healths – and remember the human right to
enjoy the beneﬁts of science and its applications. Secondly,
one must bear in mind the unknown challenges of germline
alterations and the potential for discrimination that justify the
r See The Guardian news article here: http://www.theguardian.
com/science/2010/feb/17/desmond-tutu-genome-genetic-
diversity.
s See WHO  Fact sheet n◦323 available here: http://www.who.int/
mediacentre/factsheets/fs323/en/.
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eneral prohibition that is in place today and that is likely
o be maintained and perhaps even strengthened in inter-
ational law in the future.50,109,110 Importantly, this issue is
inked with the broader issue of human enhancement that
as been the subject of intense debate since the HGP and will
ertainly continue to be for years to come.
In parallel, the potential for genetic discrimination in
he context of the personalized medicine endeavor is never
omplete without addressing the issue of data privacy. This
atter is very complex and cannot be looked at in isola-
ion from broader social phenomena that point toward an
rosion of privacy in our daily lives. Furthermore, the issue
f privacy is recurrent whether we  discuss research, diag-
osis or therapy.111 A good example is that of companies
ffering DTC genetic tests, which aim to or do already run
iobanks for research purposes. The possibility that individ-
al information, including genetic information, present in
iobank databases is coupled with private health data and
eld by proﬁt-oriented entities raises important ethical
nd legal questions in terms of transparency and data pro-
ection regulation. Additionally, raw genetic information, held
y institutions should not only be protected from access by
hird parties without consent but also be accessible by the
ndividuals from which that information was derived.66,112,113
his discussion is fundamental whether one defends the par-
icular nature of genetic information or whether one sees
enetic data as similar to any other health data.21,45,114,115
herefore, the issue of genetic privacy is central to the person-
lized medicine debate and its particular challenges should be
ddressed in order to gather public trust and approximate the
dvancement of science and technology to societal concerns,
rinciples and values. Finally, these fundamental premises,
he nature of DNA and genetic information and the approxi-
ation of science and society, are also central to a debate that
annot be developed here but which is of ethical and legal
elevance as well – the issue of patenting of human genes.
his debate has signiﬁcant ramiﬁcations and recent develop-
ents on the subject deserve a dedicated analysis, which can
e found elsewhere.116,117 0 1 4;3 2(2):164–180 171
Conclusion
Scientiﬁc progress is exponential and so are its highest
promises and subversive potential when it is used abusively.
We  must bear in mind that the same progress that has led to
enormous gains in terms of both quantity and quality of life
throughout the years, has also permitted that a great deal of
destructive behavior hindered science’s most altruistic efforts.
Estimating the potential for progress and disruption involves
not only analyzing current developments by different social,
cultural and historical perspectives but also embarking on
prognosis exercises to envisage future tendencies. Both these
exercises are very complex and prone to error and bias and
therefore must be approached with caution. However, com-
plexity should not serve as an excuse for inaction. History is
full of examples where abusive uses technology and science or
the misrepresentation of its aims led to great problems and in
some cases suffering. Also in the case of genetics and person-
alized medicine we must make sure that we  have collectively
learned from those episodes. We can start by distinguishing
hope from hype and ﬁnding in law and ethics essential allies
to limit the later and potentiate the former.
Final  note
In Portugal, some of the most relevant ethical and legal
challenges discussed above have been subject to dedicated
legislation and the opinion of important national ethics bod-
ies. The general solutions of the Portuguese ethical and legal
framework in this context, some of which are very unique,118
together with the corresponding main normative instruments
for each example discussed in this article, are presented in
Table 1.Conﬂicts  of  interest
The authors have no conﬂicts of interest to declare.
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Table 1 – Summary of the Portuguese ethical and legal framework on some of the most relevant ethical and legal challenges of personalized medicine. Examples of
research (biobanks), prevention and diagnosis (genetic tests), and treatment (gene therapy) are presented, as well as other relevant general norms. The corresponding
main normative instruments for each example are also indicated.
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
General Legal and regulatory documents
- Constitution of the
Portuguese Republic (CRP);
- Portuguese Penal Code;
- Portuguese Civil Code;
- Health Basis Law (Law 48/90
of 24 August);
- Law 12/2005 of 26 January on
personal genetic information
and health information;
- Law 67/98 of 26 October on
the protection of personal data;
- Law 21/2014 of 16 April on
clinical research
-  Norm 015/2013 of the
Directorate-General of Health
on informed consent for
treatment, diagnosis and
participation in research
studies
- Norm 16/DSMIA (2001) of the
Directorate-General of Health
on informed consent in
pre-natal diagnosis
Opinions of the National Council
of Ethics for the Life Sciences
- 43/CNECV/2004 on personal
genetic information and health
information;
- General principle – the moral
and physical integrity of every
individual is inviolable. The
law protects individuals
against any illicit offense or
threat to their physical and
moral personality. (CRP, art.
25/1; Civil Code, art. 70);
- Informed consent excludes
the unlawfulness of the act
when it refers to freely
disposable legal interests and
the act does not offend social
mores. Presumed consent
equals express consent when it
can be reasonably assumed
that the agent would have
consented under those speciﬁc
circumstances. Minimum age
for valid consent is 16 years
old. (Penal Code, arts. 38, 39;
Civil Code, art. 340);
- Every patient has the right to
consent or refuse health care
and to be informed about
his/her situation, alternative
treatment and prognosis
(Health Basis Law -Law 48/90,
Base XIV/1/a, b):
- Informed consent rules in the
case of medical-surgical
treatments and the duty to
inform and clarify (Penal Code,
arts. 149, 150, 156, 157).
-  Everyone shall possess the right to
protect the privacy of their personal and
family life (CRP, art. 26/1);
- General principle - the processing of
health and genetic data is prohibited.
Exceptions: other legal provisions; express
consent from the data subject; vital
interests of the data subject in the case of
incapacity; National Data Protection
Authority (CNPD) authorization on the
grounds of public health interest provided
that non-discrimination and security
measures are implemented; necessity for
the purposes of preventive medicine,
medical diagnosis, treatment or the
management of health-care services
provided that information is processed by
an individual bound by professional
secrecy and CNPD is notiﬁed (Law 67/98,
arts. 7, 15, 27);
- Processing of health and genetic
information must respect all adequate
measures to protect conﬁdentiality
(includes security of the premises,
equipment and information) and to
enforce the professional duty of
conﬁdentiality (Law12/2005, art. 4/1);
- Health information can only be used
with written authorization from the
person to whom it pertains (or legal
representative) (Law12/2005, art. 4/3);
- Genetic information must be subject to
legislative and administrative measures
of reinforced protection in terms of
access, security and conﬁdentiality
(Law12/2005, art.6/6);
-  Fundamental principle –  dignity of the human
person (CRP, art. 1);
- Everyone shall possess the right to legal
protection against any form of discrimination
(CRP, art. 26/1);
- The law shall guarantee the personal dignity
and genetic identity of the human person,
particularly in the creation, development and
use of technologies and in scientiﬁc
experimentation (CRP, 26/3);
- Health information, including genetic data is
property of the person to whom it pertains and it
cannot be used for any other purposes than
health care and health related research, or other
purposes deﬁned by law (Law 12/2005, art. 3/1);
- Stored biological material remains property of
the person from whom it was collected and, in
case of death or incapacity, of his/her relatives
(Law 12/2005, arts. 18/2, 19/13);
- In special circumstances, when information is
important for the treatment or the prevention of
a genetic disease in the family, information can
be used in the context of genetic counseling –
even if it is no longer possible to obtain the
informed consent from the person to whom it
belongs (Law 12/2005, art. 18/6);
- Relatives in direct line of ascent or descent, as
well as second degree relatives, can access a
stored sample of genetic material, in case it is
necessary to obtain a better knowledge of their
own genetic status, but not to know the genetic
status of the person to whom the sample
pertains or of other family members (Law
12/2005, art. 18/7);
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Table 1 (Continued)
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
- 56/CNECV/2008 on the direct
sale of genetic tests to the
public
- 68/CNECV/2012 on genetic
information, genetic databases
and genetic tests;
- 57/CNECV/09 on the rights of
patients to information and
informed consent.
-  Health and genetic information must be
separated from the remaining personal
information, namely through different
levels of access (Law 67/98, art. 15/3,
Law12/2005, art. 4/5);
- The access to health and genetic data by
the person to whom it pertains, or by a
third party with consent, is made through
an authorized physician chosen by the
owner of the information (Law 67/98, art.
11/5, Law 12/2005, art. 3/3).
-  The commercial use, the patent registration or
any type of ﬁnancial gains derived from
biological samples, as such, is strictly forbidden
(Law 12/2005, art. 18/8);
- Human genetic heritage is not patentable (Law
12/2005, art. 20);
- Principle of non-discrimination – no one can be
discriminated due to the presence of a genetic
disease or due to his/her genetic heritage (Law
12/2005, art. 11/1);
- Promotion of research, protection of personal
genetic identity, clinical and analytical
validation of genetic tests, the response to drugs,
as well as genetic screening tests, will be object
of future speciﬁc regulation (Law 12/2005, art.
22/2) - these regulations are still lacking but are
expected to be published during 2014.
Research:
Biobanks
Legal documents
- Law 12/2005 of 26 January on
personal genetic information
and health information;
- Law 67/98 of 26 October on
the protection of personal data;
- Law 21/2014 of 16 April on
clinical research.
Opinions of the National Council
of Ethics for the Life Sciences
- 43/CNECV/04 on personal
genetic information and health
information;
- 68/CNECV/2012 on genetic
information, genetic databases
and genetic tests.
-  Written and express consent
(given by a competent person
or the legal representative of
an incompetent one) is
mandatory for inclusion in
research biobanks and involves
the necessary explanation
about the nature and aims of
the research, person
responsible, procedures and
potential risks and beneﬁts.
The use of samples for other
aims requires re-consent or
irreversible anonymization
(Law 12/2005, arts. 16/4, 18/4,
art. 18/5, 19/5);
- Collection of biological
products is subject to separate
informed consents for health
care purposes and for
biomedical research purposes;
the consent must include the
- Only anonymized health information
can be accessed for research purposes
(Law 12/2005, art. 4/4);
- Regulation of the creation, maintenance,
management and security of genetic
databases for health research must  follow
the protection of personal data law (Law
12/2005, art. 7/2)
;
- Privacy and conﬁdentiality of samples
and data must always be ensured;
particularly by avoiding storage of
identiﬁed material, controlling access to
the collections and guaranteeing safety in
terms of losses, changes and destruction
(Law 12/2005, art. 19/8);
- Only anonym or irreversibly
anonymized samples can be used. The
use of identiﬁed or identiﬁable samples
should be limited to studies that cannot
Deﬁnition of biobanks (Law 12/2005, art. 19/1);
- No one can collect or use human biological
samples or its by-products with the purpose of
creating a biobank without authorization from
an entity accredited by the health authorities
and by the CNPD if the biobank is associated to
personal information (Law 12/2005, art. 19/2);
- Biobanks should only be created for providing
health care services (including diagnosis and
prevention) or basic or health related research
(Law 12/2005, art. 19/3);
- Biobanks should only accept samples in
response to requests from physicians and not
directly from subjects or their relatives (Law
12/2005, art. 19/4);
- The conservation of samples of dried blood on
paper obtained in neonatal screenings or others,
must be considered in the light of the potential
beneﬁts and risks it poses to individuals and
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Table 1 (Continued)
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
purpose of the collection, the
duration of storage of the
samples and its by-products
and mention the possible
disclosure of the results (Law
12/2005, arts.18/1, 19/5);
- Informed consent can be
withdrawn at any time. In case
of death or incapacity relatives
can withdraw consent. In both
cases all samples and its
by-products must be
permanently destroyed (Law
12/2005, art.18/3);
-  In the case of retrospective
use of samples, or in special
situations in which it is not
possible to obtain consent from
the persons involved (due to
the amount of data or of
subjects, to their age or similar
reasons) the material and the
data can only be processed for
the purposes of scientiﬁc
research or for collecting
epidemiological or statistical
data (Law 12/2005, art. 19/6).
be  conducted in any other way (Law
12/2005, art. 19/9);
- Commercial entities are not allowed to
use samples that have not been
anonymized (Law 12/2005, art. 19/10);
- If there is an absolute need to use
identiﬁed or identiﬁable samples, these
should be coded and the identifying
codes must be kept separately, but always
in a public institution (Law 12/2005, art.
19/11);
- If the biobank has identiﬁed or
identiﬁable samples and if the
communication of studies results can be
foreseen, a medical geneticist should be
involved in the process (Law 12/2005, art.
19/12).
- Genetic databases and records that
allow the identiﬁcation of family
members must be managed and
supervised by a medical geneticist or
another physician if the former is not
available (Law 12/2005, art. 7/3).
society; those collections can be used for family
studies in the context of genetic counseling or
for genetic research, if they are previously and
irreversibly anonymized (Law 12/2005, art. 19/4);
- Stored biological material is considered to be
property of the person from whom it was
collected and, in case of his/her death or
incapacity, of his/her family members; the
material should be stored for as long as it proves
useful for present and future relatives (Law
12/2005, art. 19/13);
- Researchers responsible for the studies on
samples stored in biobanks should verify that
the rights and interests of the persons to whom
the biological material pertains are protected;
this includes the protection of privacy and
conﬁdentiality, but also the preservation of the
samples that may be necessary to diagnose
family diseases in the future (Law 12/2005, art.
19/14);
- Researchers responsible for biobanks have the
duty to watch over their conservation and
integrity and to inform the person from whom
consent was obtained of any loss, change or
destruction, as well  as of the decision to
abandon the research or to close the biobank
(Law 12/2005, art. 19/15);
- The law must deﬁne rules for licensing and
quality assurance of biobanks (Law 12/2005, art.
19/16) – these regulations are still lacking but are
expected to be published during 2014;
- The transfer of a large number of samples or
collections to other national or foreign entities
must respect the original purposes of the
biobank and for which consent was obtained,
and must also be approved by the responsible
ethics commissions (Law 12/2005, art. 19/17);
r
 e
 v
 p
 o
 r
 t
 s
 a
 ú
 d
 e
 p
 ú
 b
 l
 i
 c
 a
 .
 2
 0
 1
 4
;3
 2
(2
):164–180
 
175
Table 1 (Continued)
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
- The creation of databanks that describe a
particular population and possible data transfers
must be approved by the National Council of
Ethics for Life Sciences; if the databanks are
representative of the national population the
approval of the National Parliament is required
(Law 12/2005, art. 19/18);
- The scientiﬁc community must have free
access to the data resulting from research on the
human genome (Law 12/2005, art. 16/2);
- Research on the human genome is subject to
the approval by ethic commissions from
hospitals, universities or research institutions
(Law 12/2005, art. 16/3).
Prevention
and
diagnosis:
genetic
tests
Legal documents
- Law 12/2005 of 26 January on
personal genetic information
and health information;
- Law 67/98 of 26 October on
the protection of personal data.
Opinions of the National Council
of Ethics for the Life Sciences
- 43/CNECV/04 on personal
genetic information and health
information;
- 56/CNECV/2008 on the direct
sale of genetic tests to the
public
- 68/CNECV/2012 on genetic
information, genetic databases
and genetic tests.
-  Written express informed
consent (given by a competent
person or the legal
representative of an
incompetent one) is mandatory
to perform genetic tests (Law
12/2005, arts. 9/1, 9/2);
- Genetic testing of minors can
only be requested for their
beneﬁt, with written consent
from their parents or legal
tutors and always seeking ﬁrst
the minors own consent (Law
12/2005, art. 17/4);
- Collection of DNA samples for
genetic testing is subject to
separate informed consents for
health care purposes and for
biomedical research purposes;
the consent must include the
purpose of the collection and
the duration of storage of the
samples and its by-products.
The future use of samples for
other purposes requires
-  Only genetic information that has
immediate bearings the patient’s current
status of health can be registered in the
medical records, except in the case
of genetic services that keep private
separate ﬁles (Law12/2005, art.6/4);
- Medical records from genetic services
containing genetic information regarding
healthy persons, cannot be accessed,
shown or consulted by physicians, other
health care professionals or staff
(Law12/2005, art.6/5);
- The existence of a link between a health
care professional and any other sector of
activity – including insurance companies,
professional entities or suppliers of goods
and services of any kind – does not
exclude compliance with conﬁdentiality
duties (Law12/2005, art.6/8);
- Every citizen has the right to know if a
medical or research record contains
genetic information about himself/herself
and his/her family, the uses of that
information and the storage time before
-  Genetic diagnostic or pharmacogenetic testing
must follow the general principles that regulate
all other health care interventions or services
(Law12/2005, art.9/1);
- The detection of the heterozygosity status
for the diagnosis of recessive diseases, the
presymptomatic diagnosis of monogenic
diseases and the tests of genetic susceptibility
in healthy persons can only be carried out by
request of a medical geneticist, following a
genetic counseling consultation (Law12/2005,
art. 9/2);
-  The results of genetic testing should only be
communicated to the person concerned or, in
case of diagnostic testing, to the legal
representative or to the person designated by the
person concerned and during a proper medical
consultation (Law12/2005, art. 9/3);
- In situations of risk of severe, late-onset
diseases with no cure or proven effective
treatment, any presymptomatic or predictive
testing must be preceded by a previous
psychological and social evaluation and by the
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Table 1 (Continued)
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
re-consent or irreversible
anonymization (Law 12/2005,
arts.18/1, 18/4, 18/5);
- Physicians have a duty to
inform about the transmission
mechanisms of genetic
diseases, and the risks for the
subject and relatives, as well as
to provide guidance for future
counseling (Law 12/2005, art.
17/7);
- Presymptomatic, predictive
and preimplantation tests
should not be performed in
persons suffering from mental
disablement and who cannot
fully appreciate the
implications of this type of
tests or give their informed
consent to its execution
(Law12/2005, art. 9/6);
- Everyone has the right to
refuse submitting to a genetic
test (Law12/2005, art. 17/2).
destruction (Law 12/2005, art.6/9);
- In the case of heterozygosity,
presymptomatic and predictive testing,
the results should only be communicated
to the person concerned and can never be
communicated to third parties without
his/her written express consent – this
also refers to other physicians or other
health care professionals who are not
involved in the process of testing of the
person in question or of his/her family
(Law 12/2005, art. 9/4);
- In case of prenatal and preimplantation
testing, the results should only be
communicated to the mother, to the
parents or to their legal representatives
(Law12/2005, art. 9/5).
follow-up of the patient after the tests results
(Law12/2005, art. 9/7);
- The frequency of the genetic counseling and
the form of the psychological and social
follow-up should be determined based on the
severity of the disease, on the usual age of onset
and on the existence, or inexistence, of a proven
treatment (Law12/2005, art. 9/8);
- No one can be discriminated due to the results
of a genetic test, including those performed with
the purpose of obtaining or maintaining a job,
subscribing health and life insurances, having
access to education, as well as for purposes of
adoption, whether regarding the adopter or the
adoptee (Law12/2005, art. 11/2, 12-14);
- Everyone has the right to receive genetic
counseling and, if appropriate, psychological
and social support, before and after submitting
to genetic tests (Law12/2005, art. 17/3);
- The right to obtain medical, psychological and
social follow-up as well as genetic counseling
cannot be affected because of a refusal to take a
genetic test (Law12/2005, art. 11/3);
- A fair and equitable access to genetic
counseling and genetic testing is guaranteed
to all and the needs of the populations that are
more strongly affected by speciﬁc genetic
diseases should be safeguarded (Law12/2005,
art. 11/4);
-  It is illicit to create any list of diseases or
genetic characteristics that may support the
request of genetic tests or of any king of genetic
screening (Law12/2005, art. 17/1);
- No predictive tests regarding late-onset
diseases and that have no cure or proven
effective preventive treatment can be requested
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Table 1 (Continued)
Relevant national normative
instruments
Informed consent Privacy and conﬁdentiality Other
for minors. Prenatal diagnosis of diseases that usually
begin in adulthood and that have no cure cannot be done
just for parental information (Law12/2005, arts. 17/5, 17/6);
- In case of genetic screening, populations and individuals
have the right to be protected against stigmatization (Law
2/2005, art. 17/8);
- Persons with special needs, including patients with
genetic pathologies and their families, are entitled to
protection in regards to healthcare information (Law
12/2005, art. 17/9);
- The government must regulate genetic tests
of heterozygosity status, presymptomatic, predictive or
prenatal and preimplantation tests, in order to avoid that
national or foreign laboratories without the support of a
multidisciplinary medical team offer them without
oversight (Law 12/2005, art. 15/1) – these regulations are still
lacking but are expected to be published during 2014;
- The Government is responsible for determining the rules
for accreditation, certiﬁcation and licensing of public and
private laboratories that perform genetic tests (Law 12/2005,
art. 15/2) –  these regulations are still lacking but are expected
to be published during 2014.
Treatment:
gene
therapy
Legal documents
- Law 12/2005 of 26 January on
personal genetic information
and health information;
- Law 67/98 of 26 October on
the protection of personal data;
- Law 21/2014 of 16 April on
clinical research.
Opinions of the National Council
of Ethics for the Life Sciences
- 43/CNECV/04 on personal
genetic information and health
information.
-  Written express informed
consent (given by a competent
person or the legal
representative of an
incompetent one) is mandatory
to participate in clinical
research trials and involves the
necessary explanation about
the nature and aims of the
research, procedures and
potential risks and beneﬁts
(Law12/2005, art. 16/4, Law
21/2014, art. 2/j, 6/1d)
- Gene therapy medical
treatments follow the general
informed consent rules.
-  Only anonymized health information
can be accessed for research purposes
(Law 12/2005, art. 4/4).
- All information in the context of a
clinical trial is conﬁdential. Those
involved in clinical studies have a duty of
secrecy regarding all personal data they
have access to. This duty remains even
after their involvement in the study is
over (Law 21/2014, art. 51).
- It is the investigator’s role to assure that
conﬁdentiality measures are in place
during preparation, conduction and
conclusion of clinical trials, namely
regarding personal information of trial
participants (Law 21/2014, art. 10/g).
-  Alterations to the human genome can only be made for
prevention or therapy (Law 12/2005, art. 8);
- Clinical trials involving gene therapy require special
authorization by the National Medicines Agency
(INFARMED) (Law 21/2014, art. 27/2a);
- Alterations of “normal characteristics” and of germ line
are forbidden (Law 12/2005, art. 8, Law 21/2014, art. 27/6);
- The scientiﬁc community must have free access to the
data resulting from research on the human genome (Law
12/2005, art. 16/2);
- Research on the human genome is subject to the approval
by ethic commissions from hospitals, universities or
research institutions (Law 12/2005, art. 16/3).
After the submission of this article an important piece of legislation was approved in Portugal that is directly related to its subject. Decreto-Lei n.◦ 131/2014 de 29 de agosto (DL 131/2014), provides the
speciﬁc regulation required by Law 12/2005 of 16 of January in terms of protection of the conﬁdentiality of genetic information, genetic databases for healthcare and health research, conditions for
offering and conducting genetic tests and the terms of genetic counseling. In accordance with this update, please refer to DL 131/2014 whenever in this table it is indicated that a speciﬁc regulation
is still lacking but expected to be published in 2014.
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